跳到正文
PharmTech Quality Systems·· 23 天前AI 评分59

AAPS PharmSci 360 2026 会议讨论 AI 验证的模型版本控制与人工签核

AI Validation Demands Version Control: AAPS PharmSci 360 2026

AI 导读

在 AAPS PharmSci 360 2026 会议上,Hubot CDMO 高级验证工程师 Manish Baviskar 指出 AI 模型会随数据改变行为,因此每个模型版本都需纳入变更控制,最终决定应由人员作出。

正文 · 原文

Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.

At AAPS PharmSci 360 2026, Manish Baviskar, senior validation engineer, Hubot CDMO, leads a Careers 360 session on building AI skills for pharmaceutical manufacturing and validation. He explains why AI-enabled systems strain the assumptions behind conventional computerized system validation.

Baviskar starts with data integrity under ALCOA++. Conventional software works from fixed control code and returns the same output for the same input, so changes are easy to trace. AI models revise their behavior as their data change. He compares this to ChatGPT, which can give a different answer each time you ask. That variability is acceptable when drafting emails or documents, but not on the production floor. “We need to control all that requirements, all that information, to make sure that whatever the input you are providing, you are getting a right output every time,” he says. The EU’s draft GMP Annex 22 follows the same logic as it keeps generative AI and large language models out of cGMP applications.

The FDA is still finalizing its AI guidance. Baviskar notes that the agency’s message so far is consistent: a person must review AI-generated data before anyone relies on it. “We can use agentic AI in managing our workflow, but the final decision should be done by some person or maybe a quality or a SME [subject matter expert],” he says. The FDA’s warning letter to Purolea Cosmetics Lab shows that expectation being enforced.

Most AI in pharma still sits in research rather than GMP operations, Baviskar says. Where it does enter GMP use, he calls for:

  • a defined user requirements specification
  • risk-based validation
  • robust installation, operational, and performance qualification testing
  • change control for every model version
  • continuous monitoring of outputs

Dynamic models need more testing than static, version-locked ones. He also stresses cross-functional fluency. AI developers need to know what documentation GMP requires, including training frequency, dataset size, and how drift and bias will be detected. Lab chemists, validation and equipment engineers, and IT staff must also agree on how data move from instruments into AI tools.

Related to this article

Ai Pulse Check

November 19th, 2026

EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.

Read more

Manufacturing Intelligence

November 17th, 2026

Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.

Read more

Manufacturing Intelligence

November 13th, 2026

Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.

Read more

PharmTech AI Pulse Check

November 10th, 2026

Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.

Read more

Drapeau's AI Deep Dive (1)

November 9th, 2026

No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.

Read more

PharmTech AI Pulse Check

November 6th, 2026

The PharmTech AI Pulse Check panel discusses why MHRA and FDA oversight of pharma AI continues past go-live, and who validates the regulators' own AI.

Read more

Workforce Survey

November 19th, 2026

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.

Read more

Two Sanofi approvals in 2 days: oral venglustat for Type 3 Gaucher and the VaxRabeo rabies vaccine.

November 19th, 2026

FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.

Read more

来源:PharmTech Quality Systems · pharmtech.com